WO2011087705A2 - Fine particle croscarmellose and uses thereof - Google Patents
Fine particle croscarmellose and uses thereof Download PDFInfo
- Publication number
- WO2011087705A2 WO2011087705A2 PCT/US2010/060749 US2010060749W WO2011087705A2 WO 2011087705 A2 WO2011087705 A2 WO 2011087705A2 US 2010060749 W US2010060749 W US 2010060749W WO 2011087705 A2 WO2011087705 A2 WO 2011087705A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- croscarmellose
- fine particle
- solid dosage
- dosage form
- less
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Definitions
- the present disclosure relates to fine particle croscarmellose and its use in various compositions such as solid dosage forms.
- Disintegrants are used to aid in the rapid break-up of material and are commonly used in solid dosage forms.
- Solid dosage forms have a variety of important applications including food and drinks (e.g, confectionery products, aromas, and sweeteners), detergents, dyes, sanitary products (e.g., laundry detergents and other cleaning products), agricultural products, pharmaceuticals, nutraceuticals, etc.
- Disintegrants assist in the rapid break-up of these solid dosage forms so that their content is quickly released into a target media.
- Swelling is believed to be a mechanism in which certain disintegrating agents (such as starch) impart the disintegrating effect.
- Wicking is believed to another mechanism in which disintegrant agents impart their disintegrating action through porosity and capillary action. Porosity provides pathways for the penetration of fluid.
- the manufacturing process is another factor which can affect dissolution.
- an active pharmaceutical or nutraceutical ingredient can be blended with a variety of excipients, subsequently lubricated and directly compressed into a tablet.
- a disintegrant used in this type of formulation must simply break the tablet apart to expose the API for dissolution.
- the API is combined with other excipients and processed with the use of a solvent (aqueous or organic) with subsequent drying and milling to produce granules.
- the resulting granules are then blended with additional excipients prior to being compressed into a tablet. Dry compaction is similar except that compression and milling are used rather than solvents to make the granules.
- Sodium carboxymethyl starch also known as sodium starch glycolate (e.g. Explotab ® , Primogel ® ) is cross-linked carboxymethyl potato starch and is believed to act as a super-disintegrant by swelling. At high concentrations, sodium carboxymethyl starch can actually increase disintegration times due to gelling.
- Cross-linked polyvinylpyrrolidone also known as crospovidone (e.g.
- Polyplasdone XL ® , Kollidon CL ® is water insoluble and hydrophilic. It is believed to act as a super-disintegrant primarily by swelling.
- croscarmellose e.g. Ac-Di-Sol ® , Nymcel ® accelerates disintegration by wicking, swelling, and some deformation recovery due to its fibrous structure.
- the present disclosure relates to fine particle croscarmellose having a median particle size (D50) of 5 pm to 36 pm and a volume mean diameter (D[4,3]) of 40 pm or less.
- the specific surface area is typically 0.3 m 2 /g or more.
- the fine particle croscarmellose has a volume mean diameter (D[4,3]) of 35 pm or less.
- the fine particle croscarmellose typically has a 10 th percentile particle size (D10) of 15 pm or less and/or a 90 th percentile particle size (D90) of 80 pm or less.
- the present disclosure relates to a fine particle croscarmellose having a median particles size (D50) of 5 pm to less than 25 pm.
- the specific surface area is typically 0.3 m 2 /g or more.
- the fine particle croscarmellose has a volume mean diameter (D[4,3]) of 35 pm or less.
- the fine particle croscarmellose typically has a 10 th percentile particle size (D10) of 15 pm or less and/or a 90 th percentile particle size (D90) of 80 pm or less.
- the fine particle croscarmellose is sodium croscarmellose.
- the fine particle croscarmellose is incorporated into a composition.
- the fine particle croscarmellose is incorporated into a solid dosage form.
- the solid dosage form can be any solid dosage form known in the art.
- the solid dosage form can be a food or added to a liquid to generate a drink.
- the solid dosage form can function to deliver aromas, flavors, and sweeteners.
- the solid dosage form can be detergent, dye, or other sanitary or cleaning product.
- the solid dosage form can contain an insecticide, a herbicide, or a fungicide.
- the solid dosage form can be pharmaceutical or nutraceutical.
- the solid dosage form is a tablet, a caplet, a capsule
- the solid dosage form is an orally disintegrating tablet (ODT).
- ODT orally disintegrating tablet
- the solid dosage form is a tablet that disintegrates in the stomach, the intestines, or other part of the body.
- the fine particle croscarmellose exists in only part of a solid dosage form.
- the fine particle croscarmellose can be included in a coating, in a layer, or as part of an internal composition to provide the controlled release of certain contents of the solid dosage form.
- the fine particle croscarmellose typically comprises from 0.1 to 25 % by weight of the solid dosage form based on the total weight of the solid dosage form. In another aspect the fine particle croscarmellose comprises from 0.1 to 10 %, from 0.1 to 5%, from 0.1. to 1 %, or about 0.5 % by weight of the solid dosage form based on the total weight of the solid dosage form. In one aspect, the solid dosage form further comprises an aroma, a dye, a flavoring, a sweetener, a detergent, a dye, a cleaner, a sanitizer, and/or an API.
- the solid dosage form can comprise any matrix known in the art, including but not limited to the group consisting of sucrose, lactose, dextrose, erythritol, fructose, isomalt, lactilol, maltilol, maltose, mannitol, sorbitol, starch, polydextrose, xylitol, calcium phosphate such as dibasic calcium phosphate, calcium carbonate, calcium silicate, silicic acid, carboxymethylcellulose, dextrin, ethylcellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, low-substituted hydroxypropyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, powdered gum Arabic, glucose, magnesium aluminum silicate, maltodextrin, methylcellulose, polymethacrylates, povidone, sodium alginate,
- the solid dosage form can further comprise a lubricant.
- the solid dosage form can also comprise one or more colorants, sweeteners, fragrances, flavor blockers, or flavor compounds, or a combination thereof.
- Figure 1 compares the disintegration time (seconds) versus compaction force (kN) for tablets containing 0.5 % by weight of fine particle croscarmellose with tablets containing 0.5 % by weight of other commercially available disintegrants.
- Figure 2 compares the disintegration time (seconds) versus compaction force (kN) for tablets containing 1.0 % by weight of fine particle croscarmellose with tablets containing 1.0 % by weight of other commercially available disintegrants.
- Figure 4 compares the disintegration time (seconds) versus compaction force (kN) for tablets containing 5.0 % by weight of fine particle croscarmellose with tablets containing 5.0 % by weight of other commercially available disintegrants.
- Figure 5 compares the disintegration time (seconds) versus compaction force (kN) for tablets containing 8.0 % by weight of fine particle croscarmellose with tablets containing 8.0 % by weight of other commercially available disintegrants.
- Figure 6 compares the disintegration time (seconds) versus compaction force (kN) for tablets containing 12.0 % by weight of fine particle croscarmellose with tablets containing 12.0 % by weight of other commercially available disintegrants.
- Figure 7 compares the disintegration time (seconds) versus compaction force (kN) for tablets containing 20.0 % by weight of fine particle croscarmellose with tablets containing 20.0 % by weight of other commercially available disintegrants.
- Figure 8 Figure 8 overlays the particle size distribution for commercially available precursor croscarmellose (Ac-Di-Sol ® ) with the particle size distribution for the fine particle croscarmellose obtained in Example 1.
- particle size distribution refers to the relative percentages by weight or volume of each of the different size fractions of a particulate matter.
- the particle size distributions for the present application can be measured using laser light diffraction equipment, such as are sold by Malvern Instruments Ltd., Malvern, Worcestershire, United Kingdom (e.g., Malvern Mastersizer ® 2000). Other types of equipment are also suitable for particle size distribution determinations.
- Laser particle size analysis measures particles using the diffraction and diffusion of a laser beam. During the laser diffraction measurement, particles are passed through a focused laser beam. These particles scatter light at an angle that is inversely proportional to their size. The angular intensity of the scattered light is then measured by a series of photosensitive detectors.
- D50 is well-known in the art and refers to the median particle size, i.e., the size where 50 volume percent of the particles have sizes less than the value given.
- D[3,2] is well-known in the art and refers to the surface area mean diameter (or Souter Mean Diameter).
- D10 is well-known in the art and refers to the 10 th percentile particle size, i.e., the particle size where 10 volume percent of the particles have sizes less than the value given.
- D90 is well-known in the art and refers to the 90 th percentile particle size i.e., the particle size where 90 volume percent of the particles have sizes less than the value given.
- solid dosage form is well-known in the art and refers to any dosage form that is a solid. Typically, the solid is dry.
- solid dosage forms include tablets, caplets, capsules (including those made from hard or soft materials such as natural or synthetic gelatin substitutes), lozenges, granules, fine granules, pills, etc.
- the solid dosage form can be used in a variety of applications.
- the solid dosage form can be a food or added to a liquid to generate a drink.
- the solid dosage form can function to deliver aromas, flavors, and sweeteners.
- the solid dosage form can be detergent, dye, or other sanitary or cleaning product.
- the solid dosage form can be a pharmaceutical or nutraceutical.
- the solid dosage form disintegrates in the stomach, the intestines, or other part of the body.
- the solid dosage form is an ODT. An ODT typically disintegrates or dissolves in the mouth within 60 seconds or less.
- the fine particle croscarmellose exists in only part of a solid dosage form.
- the fine particle croscarmellose can be included in a coating, in a layer, or as part of an internal composition to provide the controlled release of certain contents of the solid dosage form.
- the fine particle croscarmellose can be used in a coating to mask a bitter or objectionable taste.
- the solid dosage form can be an enrobed solid form comprising a film enrobing a compacted fill material having at least one API.
- the disintegrant can be used in the compacted fill material.
- Other variations of an enrobed solid form include a layered structure of API in coated pellets to control release of the API .
- the solid dosage form can be a suspension tablet.
- a suspension tablet refers to a tablet that readily disintegrates to form a suspension in liquid. Suspension tablets are useful for delivering a predetermined amount of an API in a drinkable form.
- the present disclosure is directed to fine particle croscarmellose.
- the fine particle croscarmellose can have a median particle size (D50) of less than about 36 pm, 35 pm. 34 pm. 33 pm, 32 pm, 31 pm, 30 pm, 29 pm, 28 pm, 27 pm, 26 pm, or 25 pm.
- the median particle size has a lower limit of about 5 pm, 6 pm, 7 pm, 8 pm, 9 pm, 10 pm, 11 pm, 12 pm, 13 pm, 14 pm, or 15 pm.
- the median particle size (D50) is from 5 pm to 36 pm and in another aspect is from 10 pm to 30 pm.
- the median particle size (D50) can be less than 25 pm, from 5 pm to 25 pm, or from 10 pm to 20 pm, or any combination thereof.
- the fine particle croscarmellose can have a volume mean diameter
- the volume mean diameter (D[4,3J) of about 45 pm or less.
- the volume mean diameter (D[4,3]) is less than 40.2 pm.
- the volume mean diameter (D[4,3]) has a lower limit of about 5 pm, 10 pm or 15 pm.
- the volume mean diameter (D[4,3]) is from 5 pm to 45 pm, from 10 pm to 45 pm, from 15 pm to 45 pm, from 5 pm to less than 40.2 pm, from 10 pm to less than 40.2 pm , from 15 to less than 40.2 pm, from 5 pm to 40 pm, from 10 pm to 40 pm, from 15 to 40 pm, from 5 pm to 35 pm, from 10 to 35 pm, from 15 pm to 35 pm, or from 20 pm to 30 pm, or any combination thereof.
- the fine particle croscarmellose can have a specific surface area of about 0.3 m 2 /g or more. In one aspect the specific surface area has an upper limit of about 0.8 m 2 /g. In other aspects, the specific surface area is greater than or equal to 0.35 m 2 /g, 0.4 m 2 /g, 0.45 m 2 /g, 0.5 m 2 /g, 0.55 m 2 /g, or 0.6 m 2 /g.
- the specific surface is from 0.3 m 2 /g to 0.8 m 2 /g, from 0.35 to 0.8 m 2 /g, from 0.4 m 2 /g to 0.8 m 2 /g, from 0.3 m /g to 0.7 m 2 /g, from 0.35 m 2 /g to 0.7 m 2 /g, from 0.4 m 2 /g to 0.7, from 0.3 m 2 /g to 0.6 m 2 /g, from 0.35 m 2 /g to 0.6 m 2 /g, from 0.4 m 2 /g to 0.6 m 2 /g, from 0.3 m 2 /g to 0.55 m 2 /g, from 0.4 m 2 /g to 0.55 m 2 /g, or any combination thereof.
- the fine particle croscarmellose can have a surface area mean diameter D[3,2] of about 25 pm, 24 pm, 23 pm, 22 pm, 21 pm, 20 pm, 19 pm, 18 pm, 17 pm, 16 pm, 15 pm or less.
- the surface area mean diameter D[3,2] has a lower limit of about 5 pm, 6 pm, 7 pm, 8 pm, 9, pm, 10, pm, 11 , pm, 12 pm, 13 pm, 14, pm, or 15 pm.
- the surface area mean diameter D[3,2] is less than or equal to 20 pm, 18 pm, 15 pm, or 13 pm.
- the surface area mean diameter D[3,2] is from 5 pm to 25 pm, from 5 pm to 20 pm, from pm 5 to 15 pm, or from 10 pm to 15 pm, or any combination thereof.
- the fine particle croscarmellose can have a 10 th percentile particle size (D10) of 15 pm, 14 pm, 13 pm, 12 pm, 11 pm, 10 pm or less.
- the 10 th percentile particle size (D10) has a lower limit of 5 pm, 6 pm, 7 pm, 8 pm, 9 pm, or 10 pm.
- the 10 th percentile particle size (D10) is from 5 pm to 15 pm, from 5 pm to 14 pm, from 5 pm to 13 pm, from 5 pm to 12 pm, from 5 pm to 11 pm, from 5 pm to 10 pm, or any combination thereof.
- the fine particle croscarmellose typically has a 90 th percentile particle size (D90) of less than about 85 pm.
- the 90 th percentile particle size (D90) has a lower limit of 20 pm.
- the 90 th percentile particle size (D90) is less than or equal to 80 pm, 75 pm , 70 pm, 65 pm, 60 pm, 55 pm, 50 pm, 45 pm, 40 pm, or 35 pm.
- the 90 th percentile particle size is from 20 pm to 80 pm, from 20 pm to 75 pm , from 20 pm to 70 pm, from 20 pm to 65 pm, from 25 pm to 60 pm, from 25 pm to 55 pm, from 30 pm to 50 pm, from 30 pm to 45 pm, from 30 pm to 40 pm, or from pm to 35 pm, or any combination thereof.
- the fine particle croscarmellose has:
- the fine particle croscarmellose can be sodium croscarmellose.
- the fine particle croscarmellose is incorporated into a composition for use in, for example, a solid dosage form.
- the solid dosage form contains fine particle croscarmellose in an amount less than about 25 %, 24 %, 23 %, 22 %, 21 %, 20 %, 19 %, 18 %, 17 %, 16 %, 15 %, 14 %, 13 %, 12 %, 11 %, 10 %, 9 %, 8 %, 7 %, 6 %, 5 %, 4 %, 3 %, 2 %, or 1 % by weight based on the total weight of the solid dosage form.
- the solid dosage form contains a lower limit of fine particle croscarmellose in an amount of about 0.1 %, 0.2 %, 0.3 %, 0.4 %, or 0.5 % by weight based on the total weight of the solid dosage form.
- the solid dosage form contains fine particle croscarmellose in an amount from 0.1 % to 25 %, from 0.1 % to 20 %, from 0.1 % to 15 %, from 0.1 % to 10%, from 0.1 % to 9 %, from 0.1 % to 8 %, from 0.1 % to 7 %, from 0.1 % to 6 %, from 0.1 % to 5 %, from 0.1 % to 4 %, from 0.1 % to 3 %, from 0.1 % to 2 %, or from 0.1 % to 1 % by weight based on the total weight of the solid dosage form.
- APIs include, but are not limited to: analgesics: acetaminophen, aspirin, naproxen; anti-ulcer drugs: famotidine; antiemetics: ondansetron, granisetron, dolasetron, domperidone, metoclopramide; antihypertensive drugs: enalapril, losartan, candesartan, valsartan, lisinopril, ramipril, doxazosin, terazosin; antihistaminic drugs: loratadine, cetirizine; antipsychotic drugs: risperidone, olanzapine, quetiapine; antidepressants: paroxetine, fluoxetine, mirtazapine; analgesics and anti-inflammatory drugs: piroxicam; antihypercholesterolemic drugs: simva
- An API can also be one or more of alprazolam, prednisilone, zomitriptan, selegiline, baclofen, carbidopa, levodopa, desloratadine, aripiprazole, loratadine, or donepezil.
- the solid dosage form typically has a matrix that binds and holds the ingredients together while in the solid form.
- the matrix may be a water soluble or insoluble material.
- matrix materials include dextrose, erythritol, fructose, isomalt, lactilol, maltilol, maltose, mannitol, sorbitol, starch such as corn starch, potato starch, wheat starch, rice starch, partial a-starch, modified starch, partially modified starch, pregelatinized starch, partially pregelatinized starch, starch hydrolysate, polydextrose, and xylitol.
- Spray dried sorbitol and gamma-crystalline sorbitol are useful.
- Spray-dried mannitol is a particularly useful matrix.
- the matrix can be a combination of constituents.
- One combination is spray-dried mannitol and microcrystalline cellulose.
- the matrix material can comprise calcium phosphate, dibasic calcium phosphate, precipitated calcium carbonate, calcium silicate, light anhydrous silicic acid, carboxymethylcellulose, dextrin, ethylcellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, polyvinyl pyrrolidone, powdered gum Arabic, glucose, magnesium aluminum silicate, maltodextrin, methylcellulose, polymethacrylates, sodium alginate, and zein.
- the matrix can have functions in addition to binding.
- the matrix can provide a sweet or refreshing taste.
- Spray dried mannitol is an excellent matrix and is commercially available as Pearlitol ® SD (Roquette) and MannogenTM EZ spray dried mannitol (SPI Pharma).
- Spray dried mannitol has several useful physical and chemical properties. For example, it dissolves easily in water (1 in 5.5 parts at 20 °C) and quickly (5 g dissolves in approximately 5 sec in 150 mL of water at 20 °C). Direct compression mannitol, powder mannitol, and other related saccharide excipients are slower to dissolve.
- Spray dried mannitol is substantially in the a crystalline form, whereas other forms of mannitol are generally in the ⁇ form.
- spray dried mannitol has flowability of 6 seconds, which is desirable for direct compression processes. It is highly compressible, having a Cohesion Index of 1500-2000. It also has good dilution capacity due to the size and form of the particle, which makes it possible to accept large amounts of API that are not easily compressed.
- Spray dried mannitol is very chemically stable, is non-hygroscopic, and does not form Maillard reactions with amino groups. Moreover, consumers experience a sense of freshness when taking mannitol because of its negative heat of dissolution. Spray dried mannitol has about half the sweetness of sucrose. It is also very palatability because of its small particle size.
- the solid dosage form can contain additives.
- additives include excipients, additional disintegrants, binders, acidulants, foaming agents, natural and artificial sweeteners, flavoring agents, lubricants, coloring agents, stabilizers, pH control agents, surfactants, etc.
- lubricants include magnesium stearate, stearic acid, talc, sodium stearyl fumarate, sucrose fatty acid ester, polyethylenglycol, and waxes.
- Stearic acid and polyethylene glycol (M R > 2000) are known, relatively hydrophilic, lubricants.
- Non-limiting examples of additional disintegrants include carboxymethylcellulose, calcium carboxymethylcellulose, sodium carboxymethyl starch, croscarmellose sodium, crospovidone, low-substituted hydroxypropyl cellulose, and hydroxypropyl starch.
- Non-limiting examples of acidulants include citric acid, tartaric acid, malic acid, and ascorbic acid.
- Non-limiting examples of the foaming agent include sodium hydrogen carbonate, and sodium carbonate.
- Non-limiting examples of sweeteners include aspartame, sodium cyclamate, sodium saccharine, ammonium glycyrrhizinate, neohesperidine dihydrochalcone, alitame, neotame, sucralose, stevioside, sucrose, fructose, lactose, sorbitol, and xylitol.
- Non-limiting examples of flavoring agents include flavors like menthol, mint, or fruit. Flavors such as raspberry, blackberry, cherry, black cherry, black currant, strawberry, grape, lingonberry, cantaloupe, watermelon, pear, apple, pineapple, mango, peach, apricot, plum, orange, lemon, lime, spearmint, peppermint, vanilla, and chocolate are suitable. Other flavors can include the flavor of bubblegum.
- the flavor compound can encompass a flavor enhancer, e.g. citric acid.
- Non-limiting examples of coloring agents include food colors such as food yellow No. 5, food red No. 2 and food blue No. 2, edible lake pigments, and iron sesquioxide.
- the colorants can include pigments, natural food colors and dyes suitable for food, drug and cosmetic applications. A full recitation of all F.D. & C. colorants and their corresponding chemical structures can be found in the Kirk-Othmer Encyclopedia of Chemical Technology, 3rd Edition, in volume 5 at pages 857-884, of which text is incorporated herein by reference.
- Non-limiting examples of stabilizers include disodium edetate, tocopherol, and cyclodextrin.
- Non-limiting examples of pH control agents include citrate, phosphate, carbonate, tartarate, fumarate, acetate, and salts formed with an amino acid.
- Non-limiting examples of surfactants include sodium laurylsulfate, polysorbate 80, polyoxyethylene(160), and polyoxypropylene(30)glycol.
- Fine particle croscarmellose can be prepared by any method known in the art for particle size reduction.
- fine particle croscarmellose can be prepared by sieving commercially available croscarmellose (e.g., Ac-Di-Sol ® ) through a mesh sieve.
- croscarmellose e.g., Ac-Di-Sol ®
- fine particle croscarmellose can be prepared using size-reducing equipment that relies on compression or impact. Compression is applied via moving jaws, rollers or gyratory cones. Impact-based equipment commonly uses hammers or media.
- Rolls or impact mills can be used to produce fine particle croscarmellose.
- Impact mills use revolving hammers to strike incoming particles and to break or fling them against the machine case.
- the hammers might be fixed or, more commonly, pivoted.
- the hammers can be reversed to provide added life before they need to be replaced.
- Jet mills can also be used to produce fine particle croscarmellose.
- particles strike each other as they are transported in a stream of air.
- a rotating drum propels the feed into the air where the pieces strike each other and fracture.
- Ball, pebble and rod mills are also options for producing fine particle croscarmellose.
- Ball, pebble, and rodmills are rotating cylinders that are partially filled with metal or ceramic balls, flint pebbles or rods.
- the crushing mechanism is a combination of impact with the grinding media and shearing between the media and the cylinder walls.
- a variation is a jar mill, in which relatively small ceramic containers holding some grinding media are rotated on a common machine frame.
- Some form of separation can follow size reduction.
- the most common for of separation is simple screening, in which the screen openings are selected to pass the desired size range and retain material that is too large. Screens are subject to blinding by particles large enough to enter a hole, but not able to pass through. Most screens are moved by vibration or regular motion to facilitate passage and to remove overs. Air aspiration is often used, especially in jet mills, to remove fine particles by entrainment while retaining larger particles. Hammer, ball and rod mills frequently have screens on their discharge to retain large particles and media while passing fine particles. Centrifuges or hydroclones, which rely on differences in density and particle size, are also used to separate materials after size reduction.
- Fine particle croscarmellose was prepared by sieving commercially available Ac-Di-Sol® through a 500 mesh sieve. The particle size distribution was determined by analyzing the dry powder using a Malvern Particle Size Analyzer (Mastersizer® 2000, Version 5.54, Malvern Instruments Ltd., Malvern, UK). The fine particle croscarmellose had the particle size distribution shown in the table below.
- Figure 8 overlays the particle size distribution for the commercially available precursor Ac-Di-Sol® with the particle size distribution for the fine particle croscarmellose obtained above.
- Tablets comprising fine particle croscarmellose from Example 1 and commercially available precursor croscarmellose (Ac-Di-Sol®) were prepared and their disintegration time compared with tablets comprising equivalent amounts of other commercially available disintegrants, i.e., crospovidone (PVP® XL-10), crospovidone (Kollidon® CL-SF), and sodium starch glycolate (Glycolys®).
- crospovidone PVP® XL-10
- crospovidone Kollidon® CL-SF
- sodium starch glycolate Glycolys®
- Spray-dried mannitol was obtained as Pearlitol ® 200 SD from
- each disintegrant and Pearlitol ® 200 SD were premixed in a V- blender for 15 minutes; then magnesium stearate was added and followed up with additional 2 minutes of mixing.
- each formulation was compressed individually on a Stokes 512 Tablet Press with four stations. Standard 7/16" concave punches and corresponding dies were used. Tablet weight was adjusted to 400 mg.
- SMI DirectorTM data acquisition system was used to record the compaction process. Compaction forces of 4 kN, 6 kN, 8 kN, 10 kN, or 12 kN were applied to the formulations to produce tablets with different hardness.
- the test was conducted at 37+0.5 Celsius in a medium of 10 mL distilled water.
- Hardness along with tablet weight, thickness, and diameter were determined using an AT4 automatic tablet-testing system (Dr. Schleuniger Pharmatron, Switzerland). The hardness data are reported as the mean hardness. Tablet weight and thickness were controlled in a very tight range.
- Friability (%) (Wb-Wa) / Wb ( 100
- Wb and Wa are the weights before and after friability test.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Medicinal Preparation (AREA)
Abstract
The disclosure is directed to fine particle croscarmellose and its use in various compositions such as solid dosage forms. More specifically, the present disclosure relates to fine particle croscarmellose having a median particle size of 5 μm to 36 μm and a volume mean diameter of 40 μm or less. The specific surface area is typically 0.3 m2/g or more. The fine particle croscarmellose is useful as a disintegrant.
Description
FINE PARTICLE CROSCARMELLOSE AND USES THEREOF
FIELD OF THE DISCLOSURE
[0001] The present disclosure relates to fine particle croscarmellose and its use in various compositions such as solid dosage forms.
BACKGROUND
[0002] Disintegrants are used to aid in the rapid break-up of material and are commonly used in solid dosage forms. Solid dosage forms have a variety of important applications including food and drinks (e.g, confectionery products, aromas, and sweeteners), detergents, dyes, sanitary products (e.g., laundry detergents and other cleaning products), agricultural products, pharmaceuticals, nutraceuticals, etc. Disintegrants assist in the rapid break-up of these solid dosage forms so that their content is quickly released into a target media.
[0003] There are a number of factors that affect disintegration. Swelling is believed to be a mechanism in which certain disintegrating agents (such as starch) impart the disintegrating effect. Wicking is believed to another mechanism in which disintegrant agents impart their disintegrating action through porosity and capillary action. Porosity provides pathways for the penetration of fluid.
[0004] The manufacturing process (e.g., wet granulation vs. dry granulation vs. direct compression) is another factor which can affect dissolution. For example, in a pharmaceutical application, an active pharmaceutical or nutraceutical ingredient ("API") can be blended with a variety of excipients, subsequently lubricated and directly compressed into a tablet. A disintegrant used in this type of formulation must simply break the tablet apart to expose the API for dissolution. In a wet granulation process, the API is combined with other excipients and processed with the use of a solvent (aqueous or organic) with subsequent drying and milling to produce granules. The resulting granules are then blended with additional excipients prior to being compressed into a tablet. Dry compaction is similar except that compression and milling are used rather than solvents to make the granules.
[0005] Because of the increased demands for faster dissolution, there are now available "superdisintegrants" in addition to disintegrants such as microcrystalline cellulose, starch, pregelatinized starch, and sodium bicarbonate (in
combination with citric or tartaric acids). Three major groups of superdisintegrants have been developed which disintegrate in water or aqueous fluid while producing minimal viscosity effects: (1 ) cross-linked modified starches, (2) cross-linked polyvinylpyrrolidone, and (3) cross-linked carboxymethyl cellulose.
[0006] Sodium carboxymethyl starch, also known as sodium starch glycolate (e.g. Explotab®, Primogel®) is cross-linked carboxymethyl potato starch and is believed to act as a super-disintegrant by swelling. At high concentrations, sodium carboxymethyl starch can actually increase disintegration times due to gelling.
[0007] Cross-linked polyvinylpyrrolidone, also known as crospovidone (e.g.
Polyplasdone XL®, Kollidon CL®) is water insoluble and hydrophilic. It is believed to act as a super-disintegrant primarily by swelling.
[0008] Internally cross-linked sodium carboxymethyl cellulose, also known as croscarmellose (e.g. Ac-Di-Sol®, Nymcel®) accelerates disintegration by wicking, swelling, and some deformation recovery due to its fibrous structure.
SUMMARY OF THE INVENTION
[0009] The present disclosure relates to fine particle croscarmellose. It is also directed to the use of fine particle croscarmellose as a disintegrant in various compositions such as solid dosage forms.
[0010] More specifically, the present disclosure relates to fine particle croscarmellose having a median particle size (D50) of 5 pm to 36 pm and a volume mean diameter (D[4,3]) of 40 pm or less. The specific surface area is typically 0.3 m2/g or more. In one aspect, the fine particle croscarmellose has a volume mean diameter (D[4,3]) of 35 pm or less. The fine particle croscarmellose typically has a 10th percentile particle size (D10) of 15 pm or less and/or a 90th percentile particle size (D90) of 80 pm or less.
[0011] In another embodiment, the present disclosure relates to a fine particle croscarmellose having a median particles size (D50) of 5 pm to less than 25 pm. The specific surface area is typically 0.3 m2/g or more. In one aspect, the fine particle croscarmellose has a volume mean diameter (D[4,3]) of 35 pm or less. The fine particle croscarmellose typically has a 10th percentile particle size (D10) of 15 pm or less and/or a 90th percentile particle size (D90) of 80 pm or less.
[0012] In one embodiment, the fine particle croscarmellose is sodium croscarmellose.
[0013] In another embodiment, the fine particle croscarmellose is incorporated into a composition.
[0014] In yet another embodiment, the fine particle croscarmellose is incorporated into a solid dosage form. The solid dosage form can be any solid dosage form known in the art. For instance, the solid dosage form can be a food or added to a liquid to generate a drink. The solid dosage form can function to deliver aromas, flavors, and sweeteners. The solid dosage form can be detergent, dye, or other sanitary or cleaning product. The solid dosage form can contain an insecticide, a herbicide, or a fungicide. The solid dosage form can be pharmaceutical or nutraceutical.
[0015] In one aspect, the solid dosage form is a tablet, a caplet, a capsule
(including those made from hard or soft materials such as natural or synthetic gelatin substitutes), a lozenge, a granule, a fine granule, a pill, etc. In another aspect the solid dosage form is an orally disintegrating tablet (ODT). In another aspect the solid dosage form is a tablet that disintegrates in the stomach, the intestines, or other part of the body. In one aspect, the fine particle croscarmellose exists in only part of a solid dosage form. For example, the fine particle croscarmellose can be included in a coating, in a layer, or as part of an internal composition to provide the controlled release of certain contents of the solid dosage form.
[0016] The fine particle croscarmellose typically comprises from 0.1 to 25 % by weight of the solid dosage form based on the total weight of the solid dosage form. In another aspect the fine particle croscarmellose comprises from 0.1 to 10 %, from 0.1 to 5%, from 0.1. to 1 %, or about 0.5 % by weight of the solid dosage form based on the total weight of the solid dosage form. In one aspect, the solid dosage form further comprises an aroma, a dye, a flavoring, a sweetener, a detergent, a dye, a cleaner, a sanitizer, and/or an API.
[0017] The solid dosage form can comprise any matrix known in the art, including but not limited to the group consisting of sucrose, lactose, dextrose, erythritol, fructose, isomalt, lactilol, maltilol, maltose, mannitol, sorbitol, starch, polydextrose, xylitol, calcium phosphate such as dibasic calcium phosphate, calcium carbonate, calcium silicate, silicic acid, carboxymethylcellulose, dextrin,
ethylcellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, low-substituted hydroxypropyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, powdered gum Arabic, glucose, magnesium aluminum silicate, maltodextrin, methylcellulose, polymethacrylates, povidone, sodium alginate, and zein, or a combination thereof.
[0018] The solid dosage form can further comprise a lubricant.
[0019] The solid dosage form can also comprise one or more colorants, sweeteners, fragrances, flavor blockers, or flavor compounds, or a combination thereof.
BRIEF DESCRIPTION OF THE FIGURES
[0020] Figure 1 : Figure 1 compares the disintegration time (seconds) versus compaction force (kN) for tablets containing 0.5 % by weight of fine particle croscarmellose with tablets containing 0.5 % by weight of other commercially available disintegrants.
[0021] Figure 2: Figure 2 compares the disintegration time (seconds) versus compaction force (kN) for tablets containing 1.0 % by weight of fine particle croscarmellose with tablets containing 1.0 % by weight of other commercially available disintegrants.
[0022] Figure 3: Figure 3 compares the disintegration time (seconds) versus compaction force (kN) for tablets containing 2.0 % by weight of fine particle croscarmellose with tablets containing 2.0 % by weight of other commercially available disintegrants.
[0023] Figure 4: Figure 4 compares the disintegration time (seconds) versus compaction force (kN) for tablets containing 5.0 % by weight of fine particle croscarmellose with tablets containing 5.0 % by weight of other commercially available disintegrants.
[0024] Figure 5: Figure 5 compares the disintegration time (seconds) versus compaction force (kN) for tablets containing 8.0 % by weight of fine particle croscarmellose with tablets containing 8.0 % by weight of other commercially available disintegrants.
[0025] Figure 6: Figure 6 compares the disintegration time (seconds) versus compaction force (kN) for tablets containing 12.0 % by weight of fine particle
croscarmellose with tablets containing 12.0 % by weight of other commercially available disintegrants.
[0026] Figure 7: Figure 7 compares the disintegration time (seconds) versus compaction force (kN) for tablets containing 20.0 % by weight of fine particle croscarmellose with tablets containing 20.0 % by weight of other commercially available disintegrants.
[0027] Figure 8: Figure 8 overlays the particle size distribution for commercially available precursor croscarmellose (Ac-Di-Sol®) with the particle size distribution for the fine particle croscarmellose obtained in Example 1.
DETAILED DESCRIPTION
[0028] Where the following terms are used in this specification, they are used as defined below.
[0029] The terms "comprising," "having," and "including" are used in their open, non-limiting sense.
[0030] The terms "a" and "the" are understood to encompass the plural as well as the singular.
[0031] By the term "about" when referring to a value, is meant specifically that a measurement can be rounded to the value using a standard convention for rounding numbers. For example, "about 1.5" is 1.45 to 1.54.
[0032] The term "particle size distribution" refers to the relative percentages by weight or volume of each of the different size fractions of a particulate matter. The particle size distributions for the present application can be measured using laser light diffraction equipment, such as are sold by Malvern Instruments Ltd., Malvern, Worcestershire, United Kingdom (e.g., Malvern Mastersizer® 2000). Other types of equipment are also suitable for particle size distribution determinations. Laser particle size analysis measures particles using the diffraction and diffusion of a laser beam. During the laser diffraction measurement, particles are passed through a focused laser beam. These particles scatter light at an angle that is inversely proportional to their size. The angular intensity of the scattered light is then measured by a series of photosensitive detectors.
[0033] The term "D50" is well-known in the art and refers to the median particle size, i.e., the size where 50 volume percent of the particles have sizes less than the value given.
[0034] The term ""D[4,3]" is well-known in the art and refers to the volume mean diameter.
[0035] The term "D[3,2]" is well-known in the art and refers to the surface area mean diameter (or Souter Mean Diameter).
[0036] The term "D10" is well-known in the art and refers to the 10th percentile particle size, i.e., the particle size where 10 volume percent of the particles have sizes less than the value given.
[0037] The term "D90" is well-known in the art and refers to the 90th percentile particle size i.e., the particle size where 90 volume percent of the particles have sizes less than the value given.
[0038] The term "solid dosage form" is well-known in the art and refers to any dosage form that is a solid. Typically, the solid is dry. Non-limiting examples of solid dosage forms include tablets, caplets, capsules (including those made from hard or soft materials such as natural or synthetic gelatin substitutes), lozenges, granules, fine granules, pills, etc.
[0039] The solid dosage form can be used in a variety of applications. For example, the solid dosage form can be a food or added to a liquid to generate a drink. The solid dosage form can function to deliver aromas, flavors, and sweeteners. The solid dosage form can be detergent, dye, or other sanitary or cleaning product. The solid dosage form can be a pharmaceutical or nutraceutical. In one aspect, the solid dosage form disintegrates in the stomach, the intestines, or other part of the body. In another aspect, the solid dosage form is an ODT. An ODT typically disintegrates or dissolves in the mouth within 60 seconds or less.
[0040] In another aspect, the fine particle croscarmellose exists in only part of a solid dosage form. For example, the fine particle croscarmellose can be included in a coating, in a layer, or as part of an internal composition to provide the controlled release of certain contents of the solid dosage form. The fine particle croscarmellose can be used in a coating to mask a bitter or objectionable taste. The solid dosage form can be an enrobed solid form comprising a film enrobing a compacted fill material having at least one API. The disintegrant can be used in the
compacted fill material. Other variations of an enrobed solid form include a layered structure of API in coated pellets to control release of the API .
[0041] The solid dosage form can be a suspension tablet. A suspension tablet refers to a tablet that readily disintegrates to form a suspension in liquid. Suspension tablets are useful for delivering a predetermined amount of an API in a drinkable form.
[0042] As briefly described above, the present disclosure is directed to fine particle croscarmellose. The fine particle croscarmellose can have a median particle size (D50) of less than about 36 pm, 35 pm. 34 pm. 33 pm, 32 pm, 31 pm, 30 pm, 29 pm, 28 pm, 27 pm, 26 pm, or 25 pm. In one aspect, the median particle size has a lower limit of about 5 pm, 6 pm, 7 pm, 8 pm, 9 pm, 10 pm, 11 pm, 12 pm, 13 pm, 14 pm, or 15 pm. In one aspect, the median particle size (D50) is from 5 pm to 36 pm and in another aspect is from 10 pm to 30 pm. In other aspects, the median particle size (D50) can be less than 25 pm, from 5 pm to 25 pm, or from 10 pm to 20 pm, or any combination thereof.
[0043] The fine particle croscarmellose can have a volume mean diameter
(D[4,3J) of about 45 pm or less. In one aspect the volume mean diameter (D[4,3]) is less than 40.2 pm. In other aspects the volume mean diameter (D[4,3]) has a lower limit of about 5 pm, 10 pm or 15 pm. In yet other aspects, the volume mean diameter (D[4,3]) is from 5 pm to 45 pm, from 10 pm to 45 pm, from 15 pm to 45 pm, from 5 pm to less than 40.2 pm, from 10 pm to less than 40.2 pm , from 15 to less than 40.2 pm, from 5 pm to 40 pm, from 10 pm to 40 pm, from 15 to 40 pm, from 5 pm to 35 pm, from 10 to 35 pm, from 15 pm to 35 pm, or from 20 pm to 30 pm, or any combination thereof.
[0044] The fine particle croscarmellose can have a specific surface area of about 0.3 m2/g or more. In one aspect the specific surface area has an upper limit of about 0.8 m2/g. In other aspects, the specific surface area is greater than or equal to 0.35 m2/g, 0.4 m2/g, 0.45 m2/g, 0.5 m2/g, 0.55 m2/g, or 0.6 m2/g. In yet other aspects, the specific surface is from 0.3 m2/g to 0.8 m2/g, from 0.35 to 0.8 m2/g, from 0.4 m2/g to 0.8 m2/g, from 0.3 m /g to 0.7 m2/g, from 0.35 m2/g to 0.7 m2/g, from 0.4 m2/g to 0.7, from 0.3 m2/g to 0.6 m2/g, from 0.35 m2/g to 0.6 m2/g, from 0.4 m2/g to 0.6 m2/g, from 0.3 m2/g to 0.55 m2/g, from 0.4 m2/g to 0.55 m2/g, or any combination thereof.
[0045] The fine particle croscarmellose can have a surface area mean diameter D[3,2] of about 25 pm, 24 pm, 23 pm, 22 pm, 21 pm, 20 pm, 19 pm, 18 pm, 17 pm, 16 pm, 15 pm or less. In some aspects the surface area mean diameter D[3,2] has a lower limit of about 5 pm, 6 pm, 7 pm, 8 pm, 9, pm, 10, pm, 11 , pm, 12 pm, 13 pm, 14, pm, or 15 pm. In other aspects, the surface area mean diameter D[3,2] is less than or equal to 20 pm, 18 pm, 15 pm, or 13 pm. In yet other aspects the surface area mean diameter D[3,2] is from 5 pm to 25 pm, from 5 pm to 20 pm, from pm 5 to 15 pm, or from 10 pm to 15 pm, or any combination thereof.
[0046] The fine particle croscarmellose can have a 10th percentile particle size (D10) of 15 pm, 14 pm, 13 pm, 12 pm, 11 pm, 10 pm or less. In some aspects the 10th percentile particle size (D10) has a lower limit of 5 pm, 6 pm, 7 pm, 8 pm, 9 pm, or 10 pm. In other aspects, the 10th percentile particle size (D10) is from 5 pm to 15 pm, from 5 pm to 14 pm, from 5 pm to 13 pm, from 5 pm to 12 pm, from 5 pm to 11 pm, from 5 pm to 10 pm, or any combination thereof.
[0047] The fine particle croscarmellose typically has a 90th percentile particle size (D90) of less than about 85 pm. In one aspect, the 90th percentile particle size (D90) has a lower limit of 20 pm. In other aspects the 90th percentile particle size (D90) is less than or equal to 80 pm, 75 pm , 70 pm, 65 pm, 60 pm, 55 pm, 50 pm, 45 pm, 40 pm, or 35 pm. In yet other aspects, the 90th percentile particle size (D90) is from 20 pm to 80 pm, from 20 pm to 75 pm , from 20 pm to 70 pm, from 20 pm to 65 pm, from 25 pm to 60 pm, from 25 pm to 55 pm, from 30 pm to 50 pm, from 30 pm to 45 pm, from 30 pm to 40 pm, or from pm to 35 pm, or any combination thereof.
[0048] In one embodiment the fine particle croscarmellose has:
- a median particle size (D50) of 5 pm to less than 25 pm;
- a volume mean diameter (D[4,3]) of 35 pm or less.
- a specific surface area of 0.3 m2/g or more;
- a surface area mean diameter (D[3,2]) of 20 pm or less;
- a 10th percentile particle size (D10) of 15 pm or less; and
- a 90th percentile particle size (D90) of 80 pm or less.
[0049] The fine particle croscarmellose can be sodium croscarmellose.
[0050] In another embodiment of the present disclosure, the fine particle croscarmellose is incorporated into a composition for use in, for example, a solid dosage form.
[0051] In some embodiments, the solid dosage form contains fine particle croscarmellose in an amount less than about 25 %, 24 %, 23 %, 22 %, 21 %, 20 %, 19 %, 18 %, 17 %, 16 %, 15 %, 14 %, 13 %, 12 %, 11 %, 10 %, 9 %, 8 %, 7 %, 6 %, 5 %, 4 %, 3 %, 2 %, or 1 % by weight based on the total weight of the solid dosage form. In other aspects the solid dosage form contains a lower limit of fine particle croscarmellose in an amount of about 0.1 %, 0.2 %, 0.3 %, 0.4 %, or 0.5 % by weight based on the total weight of the solid dosage form. In other aspects, the solid dosage form contains fine particle croscarmellose in an amount from 0.1 % to 25 %, from 0.1 % to 20 %, from 0.1 % to 15 %, from 0.1 % to 10%, from 0.1 % to 9 %, from 0.1 % to 8 %, from 0.1 % to 7 %, from 0.1 % to 6 %, from 0.1 % to 5 %, from 0.1 % to 4 %, from 0.1 % to 3 %, from 0.1 % to 2 %, or from 0.1 % to 1 % by weight based on the total weight of the solid dosage form.
[0052] There are no limitations with respect to the API that can be incorporated into a solid dosage form. Examples of APIs include, but are not limited to: analgesics: acetaminophen, aspirin, naproxen; anti-ulcer drugs: famotidine; antiemetics: ondansetron, granisetron, dolasetron, domperidone, metoclopramide; antihypertensive drugs: enalapril, losartan, candesartan, valsartan, lisinopril, ramipril, doxazosin, terazosin; antihistaminic drugs: loratadine, cetirizine; antipsychotic drugs: risperidone, olanzapine, quetiapine; antidepressants: paroxetine, fluoxetine, mirtazapine; analgesics and anti-inflammatory drugs: piroxicam; antihypercholesterolemic drugs: simvastatin, lovastatin, pravastatin; antimigraine drugs: zolmitriptan, naratriptan, rizatriptan; anti-epileptic drugs: lamotrigine; anti-Parkinson drugs: selegiline, apomorphine; anxiolytic drugs: diazepam, lorazepam, Zolpidem; anti-asthma drugs: zafirlukast, montelukast; erection dysfunction agents: sildenafil; both in their free base form and in their acceptable pharmaceutical salts, hydrates, solvates or isomers. An API can also be one or more of alprazolam, prednisilone, zomitriptan, selegiline, baclofen, carbidopa, levodopa, desloratadine, aripiprazole, loratadine, or donepezil.
[0053] The solid dosage form typically has a matrix that binds and holds the ingredients together while in the solid form. The matrix may be a water soluble or insoluble material. Non-limiting examples of matrix materials include dextrose, erythritol, fructose, isomalt, lactilol, maltilol, maltose, mannitol, sorbitol, starch such
as corn starch, potato starch, wheat starch, rice starch, partial a-starch, modified starch, partially modified starch, pregelatinized starch, partially pregelatinized starch, starch hydrolysate, polydextrose, and xylitol. Spray dried sorbitol and gamma-crystalline sorbitol are useful. Spray-dried mannitol is a particularly useful matrix. The matrix can be a combination of constituents. One combination is spray-dried mannitol and microcrystalline cellulose. The matrix material can comprise calcium phosphate, dibasic calcium phosphate, precipitated calcium carbonate, calcium silicate, light anhydrous silicic acid, carboxymethylcellulose, dextrin, ethylcellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, polyvinyl pyrrolidone, powdered gum Arabic, glucose, magnesium aluminum silicate, maltodextrin, methylcellulose, polymethacrylates, sodium alginate, and zein. Moreover, the matrix can have functions in addition to binding. For example, the matrix can provide a sweet or refreshing taste.
[0054] Spray dried mannitol is an excellent matrix and is commercially available as Pearlitol® SD (Roquette) and Mannogen™ EZ spray dried mannitol (SPI Pharma). Spray dried mannitol has several useful physical and chemical properties. For example, it dissolves easily in water (1 in 5.5 parts at 20 °C) and quickly (5 g dissolves in approximately 5 sec in 150 mL of water at 20 °C). Direct compression mannitol, powder mannitol, and other related saccharide excipients are slower to dissolve. Spray dried mannitol is substantially in the a crystalline form, whereas other forms of mannitol are generally in the β form. Moreover, spray dried mannitol has flowability of 6 seconds, which is desirable for direct compression processes. It is highly compressible, having a Cohesion Index of 1500-2000. It also has good dilution capacity due to the size and form of the particle, which makes it possible to accept large amounts of API that are not easily compressed. Spray dried mannitol is very chemically stable, is non-hygroscopic, and does not form Maillard reactions with amino groups. Moreover, consumers experience a sense of freshness when taking mannitol because of its negative heat of dissolution. Spray dried mannitol has about half the sweetness of sucrose. It is also very palatability because of its small particle size.
[0055] The solid dosage form can contain additives. Non-limiting examples include excipients, additional disintegrants, binders, acidulants, foaming agents, natural and artificial sweeteners, flavoring agents, lubricants, coloring agents, stabilizers, pH control agents, surfactants, etc.
[0056] Non-limiting examples of lubricants include magnesium stearate, stearic acid, talc, sodium stearyl fumarate, sucrose fatty acid ester, polyethylenglycol, and waxes. Stearic acid and polyethylene glycol (MR > 2000) are known, relatively hydrophilic, lubricants.
[0057] Non-limiting examples of additional disintegrants include carboxymethylcellulose, calcium carboxymethylcellulose, sodium carboxymethyl starch, croscarmellose sodium, crospovidone, low-substituted hydroxypropyl cellulose, and hydroxypropyl starch.
[0058] Non-limiting examples of acidulants include citric acid, tartaric acid, malic acid, and ascorbic acid.
[0059] Non-limiting examples of the foaming agent include sodium hydrogen carbonate, and sodium carbonate.
[0060] Non-limiting examples of sweeteners include aspartame, sodium cyclamate, sodium saccharine, ammonium glycyrrhizinate, neohesperidine dihydrochalcone, alitame, neotame, sucralose, stevioside, sucrose, fructose, lactose, sorbitol, and xylitol.
[0061] Non-limiting examples of flavoring agents include flavors like menthol, mint, or fruit. Flavors such as raspberry, blackberry, cherry, black cherry, black currant, strawberry, grape, lingonberry, cantaloupe, watermelon, pear, apple, pineapple, mango, peach, apricot, plum, orange, lemon, lime, spearmint, peppermint, vanilla, and chocolate are suitable. Other flavors can include the flavor of bubblegum. The flavor compound can encompass a flavor enhancer, e.g. citric acid.
[0062] Non-limiting examples of coloring agents include food colors such as food yellow No. 5, food red No. 2 and food blue No. 2, edible lake pigments, and iron sesquioxide. Furthermore, the colorants can include pigments, natural food colors and dyes suitable for food, drug and cosmetic applications. A full recitation of all F.D. & C. colorants and their corresponding chemical structures can be found in the Kirk-Othmer Encyclopedia of Chemical Technology, 3rd Edition, in volume 5 at pages 857-884, of which text is incorporated herein by reference.
[0063] Non-limiting examples of stabilizers include disodium edetate, tocopherol, and cyclodextrin.
[0064] Non-limiting examples of pH control agents include citrate, phosphate, carbonate, tartarate, fumarate, acetate, and salts formed with an amino acid.
[0065] Non-limiting examples of surfactants include sodium laurylsulfate, polysorbate 80, polyoxyethylene(160), and polyoxypropylene(30)glycol.
METHODS FOR PREPARING FINE PARTICLE CROSCARMELLOSE
[0066] Fine particle croscarmellose can be prepared by any method known in the art for particle size reduction. For example, fine particle croscarmellose can be prepared by sieving commercially available croscarmellose (e.g., Ac-Di-Sol®) through a mesh sieve. Alternatively, fine particle croscarmellose can be prepared using size-reducing equipment that relies on compression or impact. Compression is applied via moving jaws, rollers or gyratory cones. Impact-based equipment commonly uses hammers or media.
[0067] Rolls or impact mills can be used to produce fine particle croscarmellose. Impact mills use revolving hammers to strike incoming particles and to break or fling them against the machine case. The hammers might be fixed or, more commonly, pivoted. Typically, the hammers can be reversed to provide added life before they need to be replaced.
[0068] Jet mills can also be used to produce fine particle croscarmellose. In jet mills, particles strike each other as they are transported in a stream of air. For the initial reduction of large materials, a rotating drum propels the feed into the air where the pieces strike each other and fracture.
[0069] Ball, pebble and rod mills are also options for producing fine particle croscarmellose. Ball, pebble, and rodmills are rotating cylinders that are partially filled with metal or ceramic balls, flint pebbles or rods. The crushing mechanism is a combination of impact with the grinding media and shearing between the media and the cylinder walls. A variation is a jar mill, in which relatively small ceramic containers holding some grinding media are rotated on a common machine frame.
[0070] Some form of separation can follow size reduction. The most common for of separation is simple screening, in which the screen openings are selected to pass the desired size range and retain material that is too large. Screens are subject to blinding by particles large enough to enter a hole, but not able to pass through. Most screens are moved by vibration or regular motion to
facilitate passage and to remove overs. Air aspiration is often used, especially in jet mills, to remove fine particles by entrainment while retaining larger particles. Hammer, ball and rod mills frequently have screens on their discharge to retain large particles and media while passing fine particles. Centrifuges or hydroclones, which rely on differences in density and particle size, are also used to separate materials after size reduction.
[0071] The following examples illustrate embodiments of the invention but do not limit its scope.
EXAMPLES
Example 1
Preparation of Fine Particle Croscarmellose
[0072] Fine particle croscarmellose was prepared by sieving commercially available Ac-Di-Sol® through a 500 mesh sieve. The particle size distribution was determined by analyzing the dry powder using a Malvern Particle Size Analyzer (Mastersizer® 2000, Version 5.54, Malvern Instruments Ltd., Malvern, UK). The fine particle croscarmellose had the particle size distribution shown in the table below.
[0073] Figure 8 overlays the particle size distribution for the commercially available precursor Ac-Di-Sol® with the particle size distribution for the fine particle croscarmellose obtained above.
Example 2
Comparison of Fine Particle Croscarmellose with Other Disinteqrants
[0074] Tablets comprising fine particle croscarmellose from Example 1 and commercially available precursor croscarmellose (Ac-Di-Sol®) were prepared and their disintegration time compared with tablets comprising equivalent amounts of other commercially available disintegrants, i.e., crospovidone (PVP® XL-10), crospovidone (Kollidon® CL-SF), and sodium starch glycolate (Glycolys®). The
particle size distribution for the various disintegrants including the fine particle croscarmellose is presented in the table below.
[0075] Spray-dried mannitol was obtained as Pearlitol® 200 SD from
Roquette (Paris, France) which is a direct compressible mannitol, and was used as the tablet matrix. Magnesium stearate (Mallinckrodt, Hazelwood, MO) was used as a lubricant. To prepare each formulation, the ingredients were weighed according to the ratios presented in the tables below.
Tablet Formulation Using Ac-Di-Sol®
0.5 % 1 .0 % 2.0 % 5.0 % 8.0 % 12.0 % 20.0 % Tablets Tablets Tablets Tablets Tablets Tablets Tablets
Ac-Di Sol® 0.5 % 1 .0 % 2.0 % 5.0 % 8.0 % 12.0 % 20.0 %
Mannitol 98 % 97.5 % 96.5 % 93.5 % 90.5 % 86.5 % 78.5 %
Magnesium
1.5 % 1.5 % 1.5 % 1.5 % 1.5 % 1.5 % 1.5 % Stearate
Tablet Formulation Using Fine Particle Croscarmellose
0.5 % 1.0% 2.0 % 5.0 % 8.0 % 12.0 % 20.0 % Tablets Tablets Tablets Tablets Tablets Tablets Tablets
Fine Particle 0.5 % 1.0% 2.0 % 5.0 % 8.0 % 12.0% 20.0 % Croscarmellose
Mannitol 98% 97.5 % 96.5 % 93.5 % 90.5 % 86.5 % 78.5 %
Magnesium
1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% Stearate
0.5 % 1.0 % 2.0 % 5.0 % 8.0 % 12.0 % 20.0 % Tablets Tablets Tablets Tablets Tablets Tablets Tablets
Glycolys® 0.5 % 1.0 % 2.0 % 5.0 % 8.0 % 12.0 % 20.0 %
Mannitol 98 % 97.5 % 96.5 % 93.5 % 90.5 % 86.5 % 78.5 %
Magnesium
1.5 % 1.5 % 1.5 % 1.5 % 1.5 % 1.5 % 1.5 % Stearate
[0076] Each disintegrant and Pearlitol® 200 SD were premixed in a V- blender for 15 minutes; then magnesium stearate was added and followed up with additional 2 minutes of mixing. To prepare tablets, each formulation was compressed individually on a Stokes 512 Tablet Press with four stations. Standard 7/16" concave punches and corresponding dies were used. Tablet weight was adjusted to 400 mg. SMI Director™ data acquisition system was used to record the compaction process. Compaction forces of 4 kN, 6 kN, 8 kN, 10 kN, or 12 kN were applied to the formulations to produce tablets with different hardness.
[0077] Disintegration times of the tablets were determined using a Hanson
QC-21 disintegration test system. The test was conducted at 37+0.5 Celsius in a medium of 10 mL distilled water.
[0078] Hardness along with tablet weight, thickness, and diameter were determined using an AT4 automatic tablet-testing system (Dr. Schleuniger Pharmatron, Switzerland). The hardness data are reported as the mean hardness. Tablet weight and thickness were controlled in a very tight range.
[0079] Tablet friability was measured on a VanKel Friabilator rotated at 25 rpm for 5 minutes. The friability for each sample was calculated using following equation:
Friability (%) = (Wb-Wa) / Wb ( 100
where Wb and Wa are the weights before and after friability test.
[0080] All initial tablet characterization studies (hardness, disintegration time, and friability) were performed on tablets that were stored for 24 hours at ambient condition in closed plastic bags. The data are presented in the tables below and Figures 1-7.
Polyplasdone
1.472
XL-10 12.0 403.2 4.5 11.14 98.6 192.1 0.24
Polyplasdone®
0.320
INF-10 4.0 400.6 5.0 10.92 23.6 217.9
Polyplasdone®
0.553
INF-10 6.1 399.9 4.8 10.92 39.0 273.6
Polyplasdone"
0.843
INF-10 8.2 399.5 4.7 10.91 57.4 265.6
Polyplasdone®
1.188
INF-10 10.1 398.8 4.5 10.91 78.0 221.1
Polyplasdone®
1.471
INF-10 12.2 398.2 4.4 10.92 94.5 199.1
Kollidon® CL 4.2 399.2 4.9 10.89 24.3 0.337 130.6
Kollidon® CL 6.0 399.1 4.7 10.90 37.5 0.552 235.5
Kollidon® CL 8.2 401.9 4.5 10.91 64.5 0.978 232.9
Kollidon® CL 10.0 401.0 4.5 10.90 73.6 1.120 171.1
Kollidon® CL 12.1 400.1 4.4 10.91 98.2 1.545 191.6
Kollidon® CL-F 4.1 399.8 5.0 10.90 23.7 0.319 165.0
Kollidon® CL-F 6.1 401.4 4.8 10.90 39.4 0.554 262.6
Kollidon® CL-F 8.1 401.5 4.6 10.91 60.0 0.884 246.7
Kollidon® CL-F 10.2 400.3 4.5 10.91 80.2 1.225 225.0
Kollidon® CL-F 12.2 402.1 4.4 10.92 97.0 1.506 187.4
Kollidon® CL-
0.384
SF 4.1 405.0 5.0 10.89 28.7 242.6 0.64
Kollidon® CL-
0.639
SF 6.0 401.9 4.8 10.90 45.0 279.2 0.41
Kollidon® CL-
0.973
SF 8.1 402.1 4.7 10.92 66.5 226.9 0.40
Kollidon® CL-
1.332
SF 10.1 404.7 4.5 10.89 88.1 232.4 0.24
[0081] Data from the table above for tablets containing 0.5 % of disintegrant are shown graphically in Figure 1.
1 % DISINTEGRANT
Compaction Thick HardTensile
Force Weight -ness Diameter ness Strength Disintegration Friability (kN) (mg) (mm) (mm) (N) (Mpa) (second) (%)
Ac-Di-Sol® 4.1 397.7 5.0 11.19 24.8 0.328 11.4 0.59
Ac-Di-Sol® 6.1 397.1 4.8 11.18 41.2 0.569 13.5 0.36
Ac-Di-Sol® 8.1 398.7 4.7 11.18 61.0 0.869 18.0 0.34
Ac-Di-Sol® 10.1 402.0 4.6 1 1 .18 76.5 1.11 1 26.3 0.21
Ac-Di-Sol® 12.1 401.4 4.5 1 1.20 95.8 1.425 31.5 0.23
Polyplasdone®
0.270
XL 4.1 399.8 5.1 10.92 20.3 20.9
Polyplasdone®
0.474
XL 6.2 397.4 4.8 10.89 33.6 66.4
Polyplasdone® ~
0.804
XL 8.2 398.0 4.6 10.93 54.6 123.2
Polyplasdone®
1 .124
XL 10.2 398.9 4.5 10.93 74.3 138.9
Polyplasdone®
1.451
XL 12.1 397.8 4.4 10.94 93.7 142.7
Polyplasdone®
0.300
XL-10 4.0 400.9 5.1 11.16 23.2 111.4 0.88
Polyplasdone®
0.601
XL-10 6.1 402.6 4.9 11.15 44.1 191 .7 0.55
Polyplasdone®
0.886
XL-10 8.1 401.7 4.7 11 .16 62.5 248.2 0.43
Polyplasdone®
1.178
XL- 0 10.1 400.9 4.6 1 1.15 80.6 217.5 0.28
Polyplasdone®
1.492
XL-10 12.1 400.5 4.5 11.15 99.5 216.1 0.30
Polyplasdone®
0.326
INF-10 4.2 400.9 5.0 10.92 24.3 158.3
Polyplasdone®
0.583
INF-10 6.1 401.2 4.8 10.92 41.5 222.7
Polyplasdone"
0.899
INF-10 8.1 400.0 4.7 10.94 62.0 198.1
Polyplasdone®
1.234
INF-10 10.2 399.8 4.6 10.91 82.0 191 .3
Polyplasdone
1.506
INF-10 12.2 400.4 4.5 10.94 98.5 193.3
Kollidon® CL 4.1 404.8 5.1 10.91 23.8 0.315 23.6
Kollidon® CL 6.1 405.3 4.9 10.90 41.7 0.580 81.2
Kollidon® CL 8.1 401.5 4.6 10.91 60.3 0.887 140.9
Kollidon® CL 10.2 402.3 4.5 10.91 85.6 1.294 169.8
Kollidon® CL 12.2 400.3 4.5 10.91 102.9 1.581 147.1
Kollidon® CL-F 4.1 401.3 5.0 10.91 23.3 0.312 27.8
Kollidon® CL-F 6.1 401.3 4.8 10.90 40.5 0.569 78.9
Kollidon® CL-F 8.1 399.9 4.6 10.90 61.1 0.908 144.6
Kollidon® CL-F 10.2 399.4 4.5 10.90 81.6 1.235 178.5
Kollidon® CL-F 12.1 401.8 4.5 10.93 103.3 1.581 175.1
Kollidon® CL-
0.357
SF 4.0 401.4 5.0 10.88 26.5 168.4 0.72
Kollidon® CL-
0.646
SF 6.1 403.1 4.8 10.88 45.9 192.3 0.43
Kollidon® CL-
1.006
SF 8.1 403.5 4.6 10.87 68.0 221.1 0.36
Kollidon® CL-
1.334
SF 10.1 402.4 4.6 10.89 88.3 184.8 0.27
Kollidon® CL-
1.720
SF 12.2 403.3 4.5 10.91 111.7 181.7 0.29
Glycolys® 4.0 402.0 5.1 11.14 27.1 0.348 17.1 1.02
Glycolys® 6.0 400.8 4.9 11.15 46.5 0.635 22.4 0.52
Glycolys® 8.1 400.5 4.7 11.16 72.8 1.033 30.3 0.42
Glycolys® 10.1 399.8 4.6 11.17 95.0 1.393 40.5 0.27
Glycolys® 12.1 400.4 4.5 11.16 121.4 1.823 51.1 0.29
Fine Particle
0.323
Croscarmellose 4.0 402.2 5.0 11.00 24.4 9.0 1.18
Fine Particle
0.515
Croscarmellose 6.1 399.9 4.9 11.00 37.6 11.4 0.65
[0082] Data from the table above for tablets containing 1.0 % of disintegrant are shown graphically in Figure 2.
2 % DISINTEGRANT
Compaction Thick HardTensile
Force Weight -ness Diameter ness Strength Disintegration Friability (kN) (mg) (mm) (mm) (N) (Mpa) (second) (%)
Ac-Di-Sol® 3.9 400.9 5.1 11.17 25.1 0.322 11.7 0.85
Ac-Di-Sol® 6.1 400.6 4.9 11.17 48.1 0.656 13.6 0.50
Ac-Di-Sol® 8.2 401.4 4.7 11.18 73.6 1.041 15.0 0.33
Ac-Di-Sol® 10.2 401.1 4.6 11.17 96.6 1.403 18.1 0.29
Ac-Di-Sol® 12.2 401.6 4.5 11.18 114.7 1.708 22.9 0.23
Polyplasdone®
0.276
XL-10 4.0 399.9 5.1 11.15 21.4 13.0 0.97
Polyplasdone®
0.540
XL-10 6.1 400.6 4.9 11.15 39.5 20.2 0.48
Polyplasdone®
0.853
XL-10 8.0 404.0 4.7 11.15 60.5 24.7 0.46
Polyplasdone®
1.024
XL-10 10.0 402.4 4.6 11.16 70.6 36.3 0.37
Polyplasdone®
1.498
XL-10 12.0 402.2 4.5 11.16 100.7 60.9 0.33
Data from the table above for tablets containing 2.0 % of disintegrant are shown graphically in Figure 3.
5 % DISINTEGRANT
Compaction Thick HardTensile
Force Weight -ness Diameter ness Strength Disintegration Friability (kN) (mg) (mm) (mm) (N) (Mpa) (second) (%)
Ac-Di-Sol® 4.1 403.0 5.1 11.18 21.4 0.274 22.0 0.89
Ac-Di-Sol® 6.1 404.9 4.9 11.18 41.7 0.564 19.3 0.39
Ac-Di-Sol® 8.1 403.1 4.7 11.18 61.0 0.860 19.0 0.31
Ac-Di-Sol® 10.2 402.4 4.6 11.19 84.6 1.229 21.0 0.27
Ac-Di-Sol® 12.2 402.8 4.5 11.18 103.7 1.544 22.0 0.21
Polyplasdone®
0.201
XL-10 4.1 403.4 5.2 11.20 16.0 9.3 1.08
Polyplasdone®
0.460
XL-10 6.1 402.9 4.9 11.20 34.5 10.5 0.55
Polyplasdone"
0.729
XL-10 8.1 403.1 4.8 11.20 52.6 13.2 0.40
Polyplasdone®
1.055
XL-10 10.2 403.5 4.7 11.19 73.8 13.6 0.25
Polyplasdone®
1.378
XL-10 12.2 403.0 4.6 11.19 94.2 15.3 0.24
Kollidon® CL-
0.291
SF 4.0 400.2 5.2 10.91 22.5 14.6 0.92
Kollidon® CL-
0.666
SF 6.1 400.9 4.9 10.89 48.3 15.1 0.51
Kollidon® CL-
1.077
SF 8.2 401.4 4.7 10.90 74.6 14.6 0.42
Kollidon® CL-
1.479
SF 10.1 401.5 4.6 10.90 99.6 16.3 0.35
Kollidonv® CL-
1.858
SF 12.1 399.9 4.5 10.96 122.9 16.7 0.29
[0084] Data from the table above for tablets containing 5.0 % of disintegrant are shown graphically in Figure 4.
Data from the table above for tablets containing 8.0 % of disintegrant are shown graphically in Figure 5.
Data from the table above for tablets containing 12.0 % of disintegrant are shown graphically in Figure 6.
20 % DISINTEGRANT
Compaction Thick HardTensile
Force Weight -ness Diameter ness Strength Disintegration Friability (kN) (mg) (mm) (mm) (N) (Mpa) (second) (%)
Ac-Di-Sol® 4.0
Ac-Di-Sol® 6.0 76.4 12.52
Ac-Di-Sol® 8.2 399.5 4.9 11.07 20.0 0.275 84.4 0.34
Ac-Di-Sol® 10.2 400.4 4.7 11.01 34.3 0.494 96.4 0.29
Ac-Di-Sol® 12.2 401.3 4.6 11.00 48.5 0.714 97.1 0.22
Polyplasdone®
XL-10 4.0 25.2 10.85
Polyplasdone®
0.243
XL-10 6.1 400.9 5.3 11.03 19.3 24.3 0.91
[0087] Data from the table above for tablets containing 20.0 % of disintegrant are shown graphically in Figure 7.
[0088] Having now fully described the present invention in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious to one of ordinary skill in the art that the same can be performed by modifying or changing the disclosure within a wide and equivalent range of conditions, formulations and other parameters without affecting the scope of the invention or any specific embodiment thereof, and that such modifications or changes are intended to be encompassed within the scope of the appended claims. All publications, patents, and patent applications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains, and are herein incorporated by reference to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference.
Claims
1. Fine particle croscarmellose having:
- a median particle size of 5 pm to 36 μητι; and
- a volume mean diameter of 40 μηι or less.
2. The fine particle croscarmellose according to claim 1 having:
- a volume mean diameter of 35 pm or less.
3. The fine particle croscarmellose according to claim 1 having:
- a specific surface area of 0.3 m2/g or more.
4. The fine particle croscarmellose according to claim 1 having:
- a surface area mean diameter of 20 pm or less.
5. The fine particle croscarmellose according to claim 1 having:
a 10th percentile particle size of 15 pm or less.
6. The fine particle croscarmellose according to claim 1 having:
- a 90th percentile particle size of 80 pm or less.
7. The fine particle croscarmellose according to claim 1 having:
- a median particle size of 5 pm to less than 25 pm.
8. The fine particle croscarmellose according to claim 7 having:
a volume mean diameter of 35 pm or less.
9. The fine particle croscarmellose according to claim 7 having:
- a specific surface area of 0.3 m2/g or more.
10. The fine particle croscarmellose according to claim 7 having:
- a surface area mean diameter of 20 pm or less.
11. The fine particle croscarmellose according to claim 7 having:
a 10th percentile particle size of 15 pm or less.
12. The fine particle croscarmellose according to claim 7 having:
a 90th percentile particle size of 80 pm or less.
13. Fine particle croscarmellose having:
- a median particle size of 5 pm to less than 25 pm;
- a volume mean diameter of 35 pm or less.
- a specific surface area of 0.3 m2/g or more;
- a surface area mean diameter of 20 pm or less;
- a 10th percentile particle size of 15 pm or less; and
a 90th percentile particle size of 80 pm or less.
14. The fine particle croscarmellose according to claim 13, wherein the fine particle croscarmellose is sodium croscarmellose.
15. A composition comprising the fine particle croscarmellose of claim 1.
16. A solid dosage form comprising an active pharmaceutical or
nutraceutical ingredient (API) and the fine particle croscarmellose of claim 1 , wherein the fine particle croscarmellose is present in an amount from 0.1 to 25 % by weight based on the total weight of the solid dosage form.
17. The solid dosage form according to claim 16, wherein the fine particle croscarmellose is present in an amount from 0.1 to 10 % by weight based on the total weight of the solid dosage form.
18. The solid dosage form according to claim 17, wherein the fine particle croscarmellose is present in an amount from 0.1 to 5 % by weight based on the total weight of the solid dosage form.
19. The solid dosage form according to claim 18, wherein the fine particle croscarmellose is present in an amount from 0.1 to 1 % by weight based on the total weight of the solid dosage form.
20. The solid dosage form according to claim 19, wherein the fine particle croscarmellose is present in an amount of about 0.5% by weight based on the total weight of the solid dosage form.
21. The solid dosage form according to claim 16, further comprising a
soluble or insoluble matrix.
22. The solid dosage form according to claim 16 further comprising a matrix selected from the group consisting of sucrose, lactose, dextrose, erythritol, fructose, isomalt, lactilol, maltilol, maltose, mannitol, sorbitol, starch, polydextrose, xylitol, calcium phosphate, dibasic calcium phosphate, calcium carbonate, calcium silicate, silicic acid,
carboxymethylcellulose, dextrin, ethylcellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, low-substituted hydroxypropyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, powdered gum Arabic, glucose, magnesium aluminum silicate, maltodextrin, methylcellulose, polymethacrylates, povidone, sodium alginate, and zein, or a combination thereof.
23. The solid dosage form according to claim 16 further comprising a
lubricant.
24. The solid dosage form according to claim 16 further comprising one or more colorants, sweeteners, fragrances, flavor blockers, flavor compounds, or additional disintegrants, or a combination thereof.
25. The solid dosage form according to claim 16 that is a tablet.
26. The tablet according to claim 25 that is an orally disintegrating tablet (ODT).
27. The fine particle croscarmellose according to claim 1 produced by
attriting or sieving croscarmellose.
28. The fine particle croscarmellose according to claim 27 produced by sieving.
29. The fine particle croscarmellose according to claim 27 produced by milling.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20100843495 EP2515879A4 (en) | 2009-12-22 | 2010-12-16 | Fine particle croscarmellose and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28904809P | 2009-12-22 | 2009-12-22 | |
US61/289,048 | 2009-12-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011087705A2 true WO2011087705A2 (en) | 2011-07-21 |
WO2011087705A3 WO2011087705A3 (en) | 2011-10-20 |
Family
ID=44151454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/060749 WO2011087705A2 (en) | 2009-12-22 | 2010-12-16 | Fine particle croscarmellose and uses thereof |
Country Status (3)
Country | Link |
---|---|
US (1) | US20110150993A1 (en) |
EP (1) | EP2515879A4 (en) |
WO (1) | WO2011087705A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2588088A2 (en) * | 2010-07-02 | 2013-05-08 | Fmc Corporation, Inc. | Solid forms |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2546440T3 (en) * | 2011-08-09 | 2015-09-23 | Coloplast A/S | A pressure sensitive adhesive composition |
PL2851075T3 (en) * | 2012-05-14 | 2022-02-21 | Shionogi & Co., Ltd. | Preparation containing 6,7-unsaturated-7-carbamoylmorphinan derivative |
US20160136097A1 (en) * | 2013-07-06 | 2016-05-19 | Daicel Corporation | Ultrafast-disintegrating tablet and method for manufacturing same |
WO2022258796A1 (en) * | 2021-06-11 | 2022-12-15 | Actelion Pharmaceuticals Ltd | Dispersible tablet for oral administration |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004067004A1 (en) | 2003-01-31 | 2004-08-12 | Orexo Ab | A rapid-acting pharmaceutical composition |
US20070275058A1 (en) | 2003-10-15 | 2007-11-29 | Fuji Chemical Industry Co., Ltd. | Tablet Quickly Disintegrating in Oral Cavity |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0587744T3 (en) * | 1991-05-28 | 2003-10-20 | Mcneil Ppc Inc | Chewable composition for release of a drug |
US6024981A (en) * | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
FR2766089B1 (en) * | 1997-07-21 | 2000-06-02 | Prographarm Lab | IMPROVED MULTIPARTICULAR TABLET WITH RAPID DELIVERY |
US5904937A (en) * | 1997-10-03 | 1999-05-18 | Fmc Corporation | Taste masked pharmaceutical compositions |
CA2322315C (en) * | 1998-03-06 | 2008-09-16 | Eurand International S.P.A. | Fast disintegrating tablets |
US6099865A (en) * | 1998-07-08 | 2000-08-08 | Fmc Corporation | Croscarmellose taste masking |
GB9818782D0 (en) * | 1998-08-28 | 1998-10-21 | Crosfield Joseph & Sons | Granular compositions |
US20040013613A1 (en) * | 2001-05-18 | 2004-01-22 | Jain Rajeev A | Rapidly disintegrating solid oral dosage form |
ATE307808T1 (en) * | 1999-03-24 | 2005-11-15 | Scherer Technologies Inc R P | PHARMACEUTICAL FORMULATIONS WITH IMPROVED SOLUBILITY IN WATER |
EP1203580A4 (en) * | 1999-06-18 | 2004-06-30 | Takeda Chemical Industries Ltd | Quickly disintegrating solid preparations |
AU765526B2 (en) * | 1999-08-17 | 2003-09-18 | Novartis Consumer Health S.A. | Rapidly dissolving dosage form and process for making same |
US6599740B2 (en) * | 2000-12-15 | 2003-07-29 | Sea Run Holdings, Inc. | Method of using fish plasma components for tissue culture |
GB0204771D0 (en) * | 2002-02-28 | 2002-04-17 | Phoqus Ltd | Fast disintegrating tablets |
EP1552851A1 (en) * | 2002-06-10 | 2005-07-13 | Dainippon Pharmaceutical Co., Ltd. | Rapidly disintegrating tablet and process for producing the same |
ES2199061B1 (en) * | 2002-06-10 | 2005-02-16 | Laboratorios Vita, S.A. | TROUBLE-BASED TABLETS AND PROCEDURE FOR OBTAINING. |
US7282217B1 (en) * | 2003-08-29 | 2007-10-16 | Kv Pharmaceutical Company | Rapidly disintegrable tablets |
CA2785138A1 (en) * | 2003-10-07 | 2005-04-21 | Andrx Pharmaceuticals Llc | Rapidly disintegrating formulation |
ATE378042T1 (en) * | 2004-04-12 | 2007-11-15 | Pfizer Prod Inc | DRUGS WITH DISCOVERED TASTE IN BRUSHING MULTIPARTICLES |
US20050244493A1 (en) * | 2004-04-30 | 2005-11-03 | Withiam Michael C | Rapidly disintegrating tablets comprising calcium carbonate |
US20070196477A1 (en) * | 2004-04-30 | 2007-08-23 | Withiam Michael C | Rapidly dissolving tablets comprising low surface area calcium phosphates |
US20070196476A1 (en) * | 2004-04-30 | 2007-08-23 | Withiam Michael C | Rapidly dissolving tablets comprising low surface area titanium dioxide |
US20070196475A1 (en) * | 2004-04-30 | 2007-08-23 | Withiam Michael C | Rapidly disintegrating low friability tablets comprising silica materials |
US20050244343A1 (en) * | 2004-04-30 | 2005-11-03 | Withiam Michael C | Oral care products comprising silica |
US20050244492A1 (en) * | 2004-04-30 | 2005-11-03 | Mehra Dev K | Rapidly disintegrating tablets comprising titanium dioxide |
US20070196474A1 (en) * | 2004-04-30 | 2007-08-23 | Withiam Michael C | Rapidly disintegrating low friability tablets comprising calcium carbonate |
US20050244347A1 (en) * | 2004-04-30 | 2005-11-03 | Mehra Dev K | Oral care products comprising calcium phosphates |
BRPI0610780A2 (en) * | 2005-04-22 | 2016-09-06 | Teva Pharma | disintegrating tablet pharmaceutical formulation, and methods for treating a patient in need of olanzapine treatment, and for producing the tablet pharmaceutical formulation |
EP2022496A1 (en) * | 2007-07-16 | 2009-02-11 | Ranbaxy Laboratories Limited | Stable ropinirole compositions |
-
2010
- 2010-12-16 WO PCT/US2010/060749 patent/WO2011087705A2/en active Application Filing
- 2010-12-16 US US12/970,153 patent/US20110150993A1/en not_active Abandoned
- 2010-12-16 EP EP20100843495 patent/EP2515879A4/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004067004A1 (en) | 2003-01-31 | 2004-08-12 | Orexo Ab | A rapid-acting pharmaceutical composition |
US20070275058A1 (en) | 2003-10-15 | 2007-11-29 | Fuji Chemical Industry Co., Ltd. | Tablet Quickly Disintegrating in Oral Cavity |
Non-Patent Citations (5)
Title |
---|
"Kirk-Othmer Encyclopedia of Chemical Technology", vol. 5, pages: 857 - 884 |
DIXIT R ET AL., INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 69, no. 3, 2007, pages 370 - 377 |
See also references of EP2515879A4 |
THIBERT R ET AL., SCIENCES TECHNIQUES ET PRATIQUES STP PHARMA SCIENCES, vol. 11, no. 2, 2001, pages 123 - 128 |
VISAVARUNGROJ N ET AL., INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 62, no. 2-3, 1990, pages 125 - 131 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2588088A2 (en) * | 2010-07-02 | 2013-05-08 | Fmc Corporation, Inc. | Solid forms |
EP2588088A4 (en) * | 2010-07-02 | 2014-05-07 | Fmc Corp Inc | Solid forms |
Also Published As
Publication number | Publication date |
---|---|
US20110150993A1 (en) | 2011-06-23 |
WO2011087705A3 (en) | 2011-10-20 |
EP2515879A4 (en) | 2014-04-02 |
EP2515879A2 (en) | 2012-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230255891A1 (en) | Highly Compactable and Durable Direct Compression Excipients and Excipient Systems | |
JP5537943B2 (en) | Fast disintegrating solid preparation | |
JP5623275B2 (en) | Directly tabletable dextrose | |
US20040265375A1 (en) | Orally disintegrating tablets | |
US20060099250A1 (en) | Use of an aqueous solution of citric acid and a water-soluble sugar like lactitol as granulation liquid in the manufacture of tablets | |
WO1998002185A1 (en) | Quickly disintegrable compression-molded materials and process for producing the same | |
US20110150993A1 (en) | Fine Particle Croscarmellose and Uses Thereof | |
US20110014286A1 (en) | Mixture for producing rapidly disintegrating tablets | |
JP2012041293A (en) | Intraoral collapsible tablet containing lactobacillus or extracted ingredient thereof | |
JP2006316047A (en) | Pranlukast hydrate-containing preparation having relieved bitterness | |
US20120003304A1 (en) | Solid Forms | |
US20220087997A1 (en) | Oral Antagonist Compositions For Nicotine Burning Relief | |
JP5902677B2 (en) | Orally disintegrating tablets of erythritol and isomalt | |
JP2010155865A (en) | Orally disintegrable tablet | |
JP7360460B2 (en) | Orally disintegrating tablet and its manufacturing method | |
JP2006316051A (en) | Pranlukast hydrate-containing preparation having relieved bitterness |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2010843495 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5154/CHENP/2012 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |